Expert Insight |Dr. Zhengsheng Zou: Advances in the Diagnosis and Treatment of Drug-Induced Liver Failure

2024.03.15
Drug-induced liver injury (DILI) is a significant adverse reaction to medications, with severe cases leading to acute liver failure (ALF) and even death. DILI is the most common cause of ALF in Western countries, yet there is still a lack of simple, specific diagnostic indicators and effective treatment methods. The incidence of DILI in China is increasing year by year, related to the variety of clinical drugs, improper medication use, and insufficient awareness. During the recent closure of the 10th "Huaxia Shanghai Liver Disease Forum and Forum on the Diagnosis and Treatment of Liver Failure and its Complications," Dr. Zhengsheng Zou from the Fifth Medical Center of the PLA General Hospital shared insights into the progress of the diagnosis and treatment of drug-induced liver failure, covering its importance, etiology, pathogenic mechanisms, clinical manifestations, treatment strategies, prognosis assessment, and large-scale studies in China.
Minor clone of del(17p) as a predictor for relapse in multiple myeloma patients: A study by Jian Cui et al

Minor clone of del(17p) as a predictor for relapse in multiple myeloma patients: A study by Jian Cui et al

2024.03.15
In February 2024, a significant research article authored by Professor Gang An from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, was published in the internationally recognized journal Haematologica (IF=11.047). The study, entitled "Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma" marks a pivotal addition to the existing research on multiple myeloma, a type of blood cancer. This groundbreaking work illuminates the role of a minor clone of deletion 17p (del(17p)) in the relapse of the disease, providing critical insights that could significantly influence future treatment strategies and improve patient outcomes. The collaborative effort reflects an extensive investigation into the genetic underpinnings of multiple myeloma relapse, promising to enhance therapeutic approaches and contribute to the global endeavor to combat this challenging disease.
Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum M-protein using mass spectrometry (EasyM)

Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum M-protein using mass spectrometry (EasyM)

2024.03.14
In a groundbreaking study conducted by a collaborative team including Professor Gang An from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, their research "Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum M-protein using mass spectrometry (EasyM)" has been brought to light. Published in a reputable academic journal——Clinical Cancer Research (IF=11.5), the study emphasizes a significant advancement in the personalized treatment and prognosis assessment of patients with multiple myeloma, a field that continues to seek more precise and predictive diagnostic tools.
Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma

Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma

2024.03.14
In February 2024, a study led by Professor Gang An from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College was published in the international academic journal ——Cancer (IF=11.2). The title of the study is "Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma". The study meticulously investigates the implications of early relapse on the survival outcomes of patients, offering invaluable insights that promise to redefine treatment approaches for this complex and heterogeneous hematologic malignancy. By shedding light on the pivotal role of early relapse as a prognostic indicator, the research presents a new frontier in the tailored management of MM, aiming to improve the outcomes for patients worldwide.
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma

Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma

2024.03.14
In January 2024, a study led by Professor Gang An from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College was published in the international academic journal ——American Journal of Hematology(IF=12.8). The title of the study is "Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma". This study represents a significant leap forward in precision medicine for multiple myeloma (MM).